These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 15774321

  • 1. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H.
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [Abstract] [Full Text] [Related]

  • 2. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

  • 3. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 28; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 4. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.
    Transplantation; 2011 Jul 27; 92(2):235-43. PubMed ID: 21677600
    [Abstract] [Full Text] [Related]

  • 5. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 6. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 27; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [Abstract] [Full Text] [Related]

  • 8. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 27; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 9. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May 27; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 10. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D.
    Transplant Proc; 2005 May 27; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [Abstract] [Full Text] [Related]

  • 11. Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience.
    Chou NK, Jan CF, Chi NH, Lee CM, Wu IH, Huang SC, Chen YS, Yu HY, Tsao CI, Ko WJ, Chu SH, Wang SS.
    Transplant Proc; 2012 May 27; 44(4):897-9. PubMed ID: 22564578
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H, Hetzer R.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [Abstract] [Full Text] [Related]

  • 13. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C, Croom KF.
    Drugs; 2006 Apr 27; 66(4):547-70. PubMed ID: 16597167
    [Abstract] [Full Text] [Related]

  • 14. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
    Kovarik JM.
    Drugs Today (Barc); 2004 Feb 27; 40(2):101-9. PubMed ID: 15045032
    [Abstract] [Full Text] [Related]

  • 15. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
    Annemans L, Lemkuhl H, Tenderich G, Schulz U, Yang XL, Ricci JF, Hetzer R.
    Transplant Proc; 2007 Dec 27; 39(10):3306-12. PubMed ID: 18089377
    [Abstract] [Full Text] [Related]

  • 16. Everolimus in cardiac-transplant recipients.
    Banas B, Böger C, Krämer B.
    N Engl J Med; 2003 Dec 04; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441
    [No Abstract] [Full Text] [Related]

  • 17. Proliferation signal inhibitors in cardiac transplantation.
    Gustafsson F, Ross HJ.
    Curr Opin Cardiol; 2007 Mar 04; 22(2):111-6. PubMed ID: 17284989
    [Abstract] [Full Text] [Related]

  • 18. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 04; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 19. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments.
    Neumayer HH.
    Transplantation; 2005 May 15; 79(9 Suppl):S72-5. PubMed ID: 15880019
    [Abstract] [Full Text] [Related]

  • 20. Vascular remodeling 1 year after cardiac transplantation.
    Li H, Tanaka K, Chhabra A, Oeser B, Kobashigawa JA, Tobis JM.
    J Heart Lung Transplant; 2007 Jan 15; 26(1):56-62. PubMed ID: 17234518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.